hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor (IC50s: 2.5 μΜ for hMAO-B, 3.84 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-1 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-1 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD).
hMAO-B/MB-COMT-IN-1 (compound 3, 50 μM, 24 h) decreases in resazurin reduction in differentiated SH-SY5Y cells[1].
hMAO-B/MB-COMT-IN-1 (50 μM, 24 h) displays lysosomal toxicity by producing ROS in differentiated SH-SY5Y cells[1].
hMAO-B/MB-COMT-IN-1 (10 μM, 30 min) displays remarkable cytoprotective effects against t-BHP in differentiated SH-SY5Y cells[1].
hMAO-B/MB-COMT-IN-1 is predicted to cross the blood-brain barrier (BBB) by passive diffusion, determined by the parallel artificial membrane permeability assay (PAMPA)-BBB kit[1].
References:
[1]. Daniel Chavarria, et al. Boosting caffeic acid performance as antioxidant and monoamine oxidase B/catechol-O-methyltransferase inhibitor. Eur J Med Chem. 2022 Sep 8;243:114740.